13-I-0141
Status:Ongoing
Phase:I
Principal Investigator(s):Kathleen R Gittens
Objective:To see whether therapeutic vaccination is safe and can affect how the body responds to HIV infection.
Prevention Option(s):Therapeutic Vaccines
Study Design:Controlled, Double-blind, Placebo, Randomized
Arms and Assigned Interventions
DescriptionHIV-MAG pDNA vaccine prime and IL-12 pDNA adjuvant (2 injections with electroporation) and the rVSV HIV gag booster vaccine (2 conventional injections). Vaccine prime & IL-12 at week 0, 4, 12 and 36
Booster at week 24 and 48
Mode of DeliveryIntramuscular
ARMsExperimental
Official Code:
13-I-0141
Trial Sponsors:
NIAID, Profectus Biosciences
Start Date
End Date
April 1, 2014
April 1, 2014
Enrollment:50
Age range:
18 Years ↔
65 Years
Population:Cisgender Men, Cisgender Women, People Living with HIV